Blood Products Industry In The New Crown: Demand Rises, Upstream "Pulp" Short Pressure

At present, in the fight against the epidemic, the main products used include immunoglobulin and albumin. According to the study published in the lancet magazine, the epidemiological characteristics and clinical manifestations of 99 cases of new coronavirus pneumonia in Wuhan, China: a descriptive study. In the treatment of 99 cases of 2019-nCoV pneumonia diagnosed in Wuhan golden Yin Tan Hospital, 27% of them received static Human Immunoglobulin for Intravenous Injection (2019) treatment.

Affected by this, blood products related companies continue to flourish. From last Tuesday to Friday, Shanghai rose 19.8%, while Hua Lan rose more than 10%, while the highest increase was 30%.

The blood products sector is a small number of plates that have positive effects in the short and medium term of the epidemic, which comes from the new static demand in the short term. The medium-term comes from the improvement of the supply and demand relationship, the reduction of sales cost and the increase in product prices caused by tight supply and demand.

In the long run, the epidemic situation is expected to increase the cognition level of domestic doctors to static C, the release of terminal demand for static C, and the improvement of the cognition of national strategic assets of blood products. Besides, the possibility of appropriately releasing the upstream slurry is also possible.

How do blood products resist "new crown"?

According to the articles published in the lancet magazine, 27% of the 99 cases of 2019-nCoV pneumonia confirmed by the Wuhan golden Yin Tan Hospital were treated with static propyl chloride. According to the Boya biopharmaceutical group Limited by Share Ltd (hereinafter referred to as Boya bio), the actual data may be much higher than this data, and more than 50% of the first-line health care workers are using static propane. In addition, in albumin, 98% of the patients with new coronal pneumonia need albumin.

Why can immunoglobulin and albumin play a role in the treatment and prevention of new crown pneumonia?

Antibodies exist in human serum and plasma. Usually, after exposure to antigens such as bacteria and viruses, specific antibodies are produced in the body, some of which disappear with time, while others remain in the blood. Immunoglobulin is the chemical basis of antibody.

Related medical staff said that although the new type of coronavirus specific immunoglobulin has not been extracted, the immunoglobulin currently used is mainly human broad-spectrum immunoglobulin, which has no direct resistance to the new coronavirus, but it can enhance the immunity of human body. If the patient is infected with other pathogens at the same time, immunoglobulin can play a therapeutic role.

Generally speaking, immunoglobulin is more effective in patients with severe and severe new crown pneumonia. Professor Yu Danyang, deputy director of the infectious disease working committee of the Chinese Medical Association's internal medicine branch, and professor of Department of respiration, deputy director of Department of respiration and chief physician of the 301 General Hospital of PLA, pointed out that "mild patients need not be used." the first is to reduce the risk of secondary infection. The two is to protect the immune system from glucocorticoid and prevent new infection.

However, in February 4th, the national health and Health Committee released the "new version of coronavirus infection pneumonia diagnosis and treatment plan (trial version fifth)", immunoglobulin is still not included in the treatment plan. Immunoglobulin is only mentioned in some hospitals recommended treatment, such as Peking Union Medical College Hospital in January 25th in the treatment plan recommended immunoglobulin for severe patients.

In addition, more targeted immunoglobulins are also being developed. On February 9th, Chen Huanchun, a member of the Chinese Academy of engineering and professor of Huazhong Agricultural University, introduced the news conference of the Hubei new crown pneumonia epidemic prevention command headquarters. The Wuhan Biological Products Co., Ltd., Wuhan blood products Co., Ltd. and the Wuhan Institute of Chinese Academy of sciences are cooperating in the development of new coronavirus combined plasma and specific immunoglobulin.

Albumin has also been widely used in the epidemic. In a survey conducted by the institutions, Boya said that 98% of the patients had low serum albumin. The decrease of serum albumin led to a decrease in colloid osmotic pressure. In order to maintain normal signs, albumin must be given to patients, and albumin played an important role in symptomatic treatment.

In this outbreak, the demand for albumin in front-line hospitals has soared, and hospitals such as Wuhan's fire god hill hospital have accumulated a large amount of albumin to meet the needs of patients. In twenty-first Century, the economic news reporter called Shanghai's Lai Shi, which indicated that it had supplied the necessary blood products to the cooperative medical institutions all over the country, including Wuhan.

Upstream slurry extraction

However, in the context of soaring demand, the upper reaches of blood products have been stagnant.

The new crown disease has resulted in the suspension of pulp from the single plasma station at present. Due to the quarantine requirement, the stock plasma must be qualified again after 3 months. In 2020, the slurry volume and pulp volume are expected to be affected in the whole year. This will further affect the quantity available for sale in 2021 (at least 9-10 months from production to sale).

According to China Merchants Securities estimates, if the end of February is resumed, it will lose nearly 1 months' slurry production period, and it is likely that the slurry volume will shrink by about 8% (1/12). However, the actual impact is expected to be less than 8%, and the average frequency of the pulp workers in the whole country is 5.2 times (the data of blood transfusion Research Institute of the Chinese Academy of Medical Sciences and Beijing Union Medical College in 2015). The frequency is low (the maximum number of times is 24 times). By increasing publicity and input, it is possible to make up for the latter 3 quarters.

The short-term impact of the new coronavirus outbreaks on the blood products industry is: first, the epidemic affects traffic and start up, which may affect the plasma collection of the blood products enterprises; the two is the effect of slurry delay on the pulp delivery and the production process; the three is the extensive application of static propane in the treatment of severe cases of new coronavirus pneumonia and the prevention of front-line medical staff, and the demand is increased.

The middle and long term effects are concentrated. If the epidemic control is not clear, the recovery of pulp will be delayed further, resulting in the shortage of supply of slurry and the rising price of blood products in short supply.

At present, the new demand for the new coronavirus epidemic to static C is mainly focused on the treatment needs of critically ill patients and the preventive needs of front-line medical staff. China Merchants Securities estimates that the corresponding demand for static C is about 6%. In the first quarter, the performance of blood products enterprises will be generally better, and the more stock companies, the more benefit they will get.

It is understood that under severe epidemics, some blood products companies have resumed production. Boya biology has already arranged for production in the new year's day and resumed work in the second year of the second year. Some enterprises in Shanghai, such as lace, have been expropriated by the government for emergency use, so as to meet the needs of the epidemic. Some hospitals even get through the distributors to get goods directly from the enterprises. Some enterprises have already appeared the situation of government's requisition and unified planning.

?